PROGRAMME

Thursday, 16th May 2019

VENUE: Church "De Duif", address Prinsengracht 756 in the Amsterdam City Centre

15:00 Registration

15.30 -16.30: SATELLITE SYMPOSIUM 1
STANDARDIZATION AND PRACTICAL IMPLEMENTATION OF AI IN DR-SCREENING
Sponsors: IDx, Eyenuk and RetMarker

16:30 BREAK

16:45 SATELLITE SYMPOSIUM 2
ANTI-VEGF IN DME AND PROLIFERATIVE DIABETIC RETINOPATHY: NEW DEVELOPMENTS
Sponsor: Novartis

Chair: Hans Vingerling

16.45-17.00 N Davies (UK)
Practical implementation of comparative RCT’s in proliferative DR: Clarity and Protocol S study results

17.00-17.15 Janneke van Lith (Netherlands)
Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: The BRDME study

17.15-17.30 Reinier Schlingemann (Netherlands)
Practical implementation of comparative RCT’s in DME: Protocol T and BRDME results

17.30-17.45 Ursula Schmidt-Erfurth (Austria)
Automated analysis of OCT images in the treatment of diabetic retinopathy

17.45-18.00 Panel discussion

18.00 Symposium ends

Official opening of EASDec and the Annual Meeting Welcome Reception

VENUE: Church "De Duif" in the Amsterdam City Centre

18.00 - 19.30 Drinks reception and canapés
Advice on restaurants - recommend prebooking
FRIDAY, 17th MAY 2019

VENUE: Amsterdam UMC, location Academic Medical Center (AMC), address Meibergdreef 9 in Amsterdam

08.00  Registration

09.00  INTRODUCTION AND WELCOME
   Professor Reinier Schlingemann/Professor Rafael Simó

SESSION 1: NEW CLINICAL PERSPECTIVES

   Chaired by: Dr. Stela Vujosevic and Prof. Jakob Grauslund

Moderator’s introduction of the session

1 – van der Heijden, A (Netherlands)
Abstractid: 33
   Retinopathy prediction models in type 2 diabetes: Systematic review and external validation study

2 - Simó-Servat, O (Spain)
Abstractid: 4
   Usefulness of gaze fixation assessment for identifying subjects with type 2 diabetes at risk of dementia

3 – van Romunde, S (Netherlands)
Abstractid: 38
   Prevalence and severity of diabetic retinopathy in patients with MacTEL type 2

4 – Stratton, I (UK)
Abstractid: 44
   Aflibercept in the real world – a clinical audit of people with diabetic macular edema from 21 UK hospitals

5 – Konstantinidis, L (Switzerland)
Abstractid: 46
   Evaluation of retinal function assessed with a novel handheld instrument (RETeval) using flicker electroretinography after anti-VEGF treatment in patients with diabetic macular oedema

10.15 Introduction to EVA KOHNER LECTURE: Professor Reinier Schlingemann

10.18 EVA KOHNER LECTURE: Professor Alan Stitt

10.55  Coffee/tea break
11.25 SESSION 2: STUDIES ON VITREOUS OR AQUEOUS HUMOUR SAMPLES TO UNDERSTAND DIABETIC EYE DISEASE
Chairied by: Professor Rafael Simó and Professor Alan Stitt

11.25 Moderator's introduction of the session

1 – Simó, R (Spain)
Abstractid: 5
Usefulness of liquid biopsy of aqueous humour biomarkers in predicting anti-VEGF response in diabetic macular oedema: Results of a pilot study

2 – Friedrich, J (Netherlands)
Abstractid: 26
Expression profiles of microRNAs in the vitreous of proliferative diabetic retinopathy patients and differences with patients treated with anti-VEGF therapy

3 – Klaassen, I (Netherlands)
Abstractid: 54
Differential protein levels in vitreous of proliferative diabetic retinopathy patients treated with aflibercept and bevacizumab

Keynote 1: Max Nieuwdorp (Netherlands): The role of microbiome in health and disease

12.40 Lunch
(Poster presenters have priority for lunch)

13.15 SESSION 3: POSTER SESSION

DR Screening:
Moderators: Dr. Irene Stratton and Dr. Olga Simo-Servat

1 - Lopez Galvez, MI (Spain)
Abstractid: 1
Teleophthalmology screening programme for DR based on a centralised reading centre: Patient and healthcare professionals’ satisfaction with the grading”?

2 – Wharton, H (UK)
Abstractid: 9
Should we photograph eyes with perception of light and no perception of light during diabetic eye screening?

3 – Almeida, N (Portugal)
Abstractid: 15
Retmarker screening: new image quality algorithm immediately evaluates gradeability of images

4 – Erke, MG (Norway)
Abstractid: 16
Screening for diabetic retinopathy at an outpatient diabetes centre in Norway

5 – Byberg, S (Denmark)
Abstractid: 20
Evaluating a screening algorithm for diabetic retinopathy and the effect of glycaemic dysregulation

6 – Hamill, B (UK)
Abstractid: 29
The comparison between an automated reading and human grading of images from a handheld wide field imaging device

7 – Changulani, T (UK)
Abstractid: 34
Referral to treatment guidelines for proliferative diabetic retinopathy in Scotland: are they possible?

8 – Hamid, A (UK)
Abstractid: 41
Why do patients default eye clinic appointments after referral from the screening programme?

9 – Dale, A (UK)
Abstractid: 49
Diabetic maculopathy levels in an English county

Clinical aspects and risk factors
Moderators to be confirmed

1 – Lipatov, D (Russia)
Abstractid: 6
Dynamics of diabetic retinopathy in Russia in 2014-2017 years

2 – Stefansson, E (Iceland)
Abstractid: 8
Smart phone APP for individual risk assessment for progression of diabetic retinopathy

3 – Pomytkina, N (Russia)
Abstractid: 18
Progression of diabetic retinopathy in pregnant women with type 1 diabetes

4 – Grauslund, J (Denmark)
Abstractid: 19
DECODE EYE – Ocular and systemic complications in diabetic retinopathy

5 – Tomić, M (Croatia)
Abstractid: 28
Adipocytokines and obesity are associated with endothelial dysfunction and retinopathy development in type 1 diabetes

6 – Palarie, N (Moldova)
Abstractid: 53
Association of obesity and retinopathy in type 2 diabetes

**DR treatment**

*Moderators to be confirmed*

1 – Kotagiri, A (UK)
*Abstractid: 3*
Baseline characteristics from an observational study (DRAKO) investigating outcomes of Intravitreal aflibercept injections for treatment of diabetic macular oedema (DMO) in the UK

2 – Vergmann, AS (Denmark)
*Abstractid: 30*
Effect of panretinal photocoagulation with navigated laser on visual field in patients with treatment-naïve proliferative diabetic retinopathy

3 – Blindbæk, S (Denmark)
*Abstractid: 35*
Aflibercept and navigated versus conventional laser in diabetic macular oedema

4 – Celik, E (Turkey)
*Abstractid: 36*
Efficacy of intravitreal dexamethasone implant treatment in diabetic macular oedema refractory to intravitreal aflibercept treatment

**Laboratory and clinical experimental studies**

*Moderators: Dr Luisa Ribeiro and Dr Nicola Quinn*

1 – Bashina, I (Russia)
*Abstractid: 7*
Association between aqueous cytokines and diabetic retinopathy stage

2 – Mazzeo, A (Italy)
*Abstractid: 12*
High glucose and hypoxia-induced damage in the inner blood retinal barrier is counteracted by thiamine supplementation

3 – Balyen, LSD (Turkey)
*Abstractid: 37*
Castanea sativa extract has anti-oxidative properties: an experimental study with retinas of metabolic syndrome-induced rats

4 – Balyen, L (Turkey)
*Abstractid: 40*
Protective effect of Onosma nigricaule (Boraginaceae) on retinal oxidative and nitrosative stress in rats with metabolic syndrome

5 - Lund-Andersen, H (Denmark)
*Abstractid: 43*
Dark adaptation in humans leads to reduced oxygen saturation in the nasal peripheral retinal veins as measured with oximetry
6 – Gooding, K (Netherlands)
Abstractid: 50
A preliminary study examining albuminuria, macular thickness and glycocalyx shedding in the early stages of diabetic retinopathy in type 2 diabetes

2.50 SESSION 4: AUTOMATED GRADING
Chaired by: Professor Simon Harding and Dr. Frank Verbraak

Moderators’ introduction of the session

1 – Pratt, H (UK)
Abstractid: 52
Learning the features of diabetic retinopathy with convolutional neural networks

2 – Ramos, J (Portugal)
Abstractid: 14
Retmarker screening: alternative deep learning algorithm also increases burden reduction in diabetic retinopathy screening programs

3 – Harding, S (UK)
Abstractid: 45
The costs of screening for sight-threatening diabetic retinopathy

3.35 SESSION 5: TREATMENT OF DME
Chaired by: Dr Erke Maja Gran and Professor Lund Andersen

1 – Capone, L (Italy)
Abstractid: 22
Fluocinolone acetonide 0.2µg/day (Iluvien®) for the treatment of chronic diabetic macular oedema: an Italian real-world experience

2 – Parker, N (Northern Ireland)
Abstractid: 23
Use of Iluvien implant for diabetic macular oedema in the Belfast Health and Social Care Trust, Northern Ireland

3 – Eandi, CM (Italy)
Abstractid: 27
Characteristics of diabetic macular oedema recurrence according to different baseline OCT patterns in patients treated with dexamethasone Implant

4 – Schlingemann, RO (Netherlands)
Abstractid: 51
Comparing the efficacy of bevacizumab to ranibizumab in patients with diabetic macular edema: The BRDME study.

5 – Vader, MJC (Netherlands)
Abstractid: 32
Cost-utility of bevacizumab versus ranibizumab in patients with diabetic macular edema: analysis from the BRDME study

4.45 Debate: Corticosteroids vs anti-VEGF in DME tbc

5.10 ANNUAL GENERAL MEETING
Moderator: Professor Reinier Schlingemann/ Dr Stela Vujosevic

Including 5.15 -5.20: Dr Lokman Balyen: Presentation from the winner of the 2017 EASDec skills award

7.00 CONFERENCE DINNER
VENUE: Hermitage, address Amstel 51 in the Amsterdam City Center

SATURDAY, 18th MAY 2019
VENUE: Amsterdam UMC, location Amsterdam Medical Center (AMC), address Meibergdreef in Amsterdam

08.30 Registration

09.00 SESSION 6: LAB – session 2
Chaired by: Dr Ingeborg Klaassen and Prof. Reinier Schlingemann
Moderators’ introduction of the session

1 – Fresia, D (Switzerland)
Abstractid: 13
Role of ER stress in hypoglycaemia-induced mouse retina cell death

2 – Porcu, M (Belgium)
Abstractid: 24
Cell-type specific insights into the Akimba model of diabetic retinopathy using single cell transcriptomics analysis

3 – Cagiltay, E (Turkey)
Abstractid: 48
Choroidal thickness significantly changes after oral glucose tolerance test in subjects with prediabetes: a spectral domain optical coherence tomography study

4 – Ribeiro, L (Portugal)
Abstractid: 10
Multimodal imaging of the initial stages of diabetic retinopathy. Different disease pathways in different patients
5 - Winner of the best student abstract price – Eyre, JJ (UK)
Abstractid: 47
Incorporation of endothelial colony forming cells into an in vitro human primary co-culture model of diabetic retinopathy

10.25 KEYNOTE LECTURE: Dr. Ingeborg Klaassen: Liquid biopsy and diabetic retinopathy

Coffee/tea break

11.30 SESSION 7: Imaging
Chaired by: Dr. Ali Erginay and Dr. Amber van der Heijden
Moderators’ introduction of the session

1 – Vujosevic, S (Italy)
Abstractid: 11
Early detection of microvascular changes in patients with diabetes mellitus without and with diabetic retinopathy: comparison between different swept-source OCT-A instruments

2 – Erginay, A (France)
Abstractid: 39
Rapid macular capillary loss in young patients with uncontrolled type 1 diabetes

3 – Quinn, N (Northern Ireland)
Abstractid: 25
Clinical characteristics of the peripheral retina in people with diabetes

4 – Byberg, S (Denmark)
Abstractid: 31
Optos wide-field imaging versus conventional camera imaging in Danish patients with type 2 diabetes

5 – Hafner, J (Austria)
Abstractid: 2
Presence of peripheral lesions and correlation to macular perfusion, oxygenation and neurodegeneration in early type 2 diabetic retinal disease

Debate: Fundus fluorescein angiography versus imaging the diabetic eye with OCT-A and/or widefield imaging
FFA: Prof. Jakob Grauslund
OCT-A/wide field imaging: tbc

12.45 Best poster prize ceremony and closing remarks
Professor Rafael Simó